Ads
related to: new antipsychotic approved medicine list printableeverydayhealth.com has been visited by 10K+ users in the past month
"Shop around for the best prices without a membership fee." - Today
Search results
Results from the WOW.Com Content Network
Print/export Download as PDF; Printable version; ... Following is a list of antipsychotics, sorted by class. Antipsychotics Antipsychotics by class Generic name ...
Saphris – atypical antipsychotic used to treat schizophrenia and bipolar disorder; Serax – anti-anxiety medication of the benzodiazepine class, often used to help during detoxification from alcohol or other addictive substances; Serentil (mesoridazine) – an antipsychotic drug used in the treatment of schizophrenia [1]
This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication. The list is not exhaustive and not all drugs are used regularly in all countries.
This is a list of investigational antipsychotics, or antipsychotics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. This list was last comprehensively updated in December 2017.
This is an alphabetical list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress. The list is not exhaustive. All mentioned drugs here are generic names. Not all drugs listed are used regularly in all countries.
In September 2024, it was approved for medical use in the United States. [1] [2] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. [2] [3]
This is a list of investigational autism and pervasive developmental disorder drugs, or drugs that are currently under development for clinical use in the treatment of autistic spectrum disorders and/or other pervasive developmental disorders but are not yet approved.
These data suggest that mGlu2/3 receptor agonists have antipsychotic properties and may provide a new alternative for the treatment of schizophrenia. [5] Other NMDA receptor modulators are being studied and this modality of treatment may once approved as antipsychotic medications gradually replace the current (dopaminergic) antipsychotics.